OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Kevin Christian Montecillo Gulay, Xinlian Zhang, Vasiliki Pantazopoulou, et al.
Cancer Research (2023) Vol. 83, Iss. 18, pp. 3001-3012
Open Access | Times Cited: 36
Kevin Christian Montecillo Gulay, Xinlian Zhang, Vasiliki Pantazopoulou, et al.
Cancer Research (2023) Vol. 83, Iss. 18, pp. 3001-3012
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
Changfeng Li, Yuanda Liu, Chang Liu, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 783
Closed Access | Times Cited: 2
Changfeng Li, Yuanda Liu, Chang Liu, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 783
Closed Access | Times Cited: 2
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
A ferroptosis amplifier based on triple-enhanced lipid peroxides accumulation strategy for effective pancreatic cancer therapy
Mengyao Chen, Xiaohan Tong, Yanting Sun, et al.
Biomaterials (2024) Vol. 309, pp. 122574-122574
Closed Access | Times Cited: 14
Mengyao Chen, Xiaohan Tong, Yanting Sun, et al.
Biomaterials (2024) Vol. 309, pp. 122574-122574
Closed Access | Times Cited: 14
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 7
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai
Cells (2024) Vol. 13, Iss. 7, pp. 602-602
Open Access | Times Cited: 7
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Macroautophagy/autophagy promotes resistance to KRASG12D-targeted therapy through glutathione synthesis
Leng Han, Lingjun Meng, Jiao Liu, et al.
Cancer Letters (2024) Vol. 604, pp. 217258-217258
Open Access | Times Cited: 5
Leng Han, Lingjun Meng, Jiao Liu, et al.
Cancer Letters (2024) Vol. 604, pp. 217258-217258
Open Access | Times Cited: 5
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology
Jihao Xu, Minh Duc Pham, Vincenzo Corbo, et al.
Experimental & Molecular Medicine (2025)
Open Access
Jihao Xu, Minh Duc Pham, Vincenzo Corbo, et al.
Experimental & Molecular Medicine (2025)
Open Access
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway
Miao Hao, Tian‐Xing Zhang, Dan Dong, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
Miao Hao, Tian‐Xing Zhang, Dan Dong, et al.
Medical Oncology (2025) Vol. 42, Iss. 5
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Inhibition of GTPase KRAS G12D : a review of patent literature
Yuhang Li, Le Yang, Xiaoran Li, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 701-721
Closed Access | Times Cited: 4
Yuhang Li, Le Yang, Xiaoran Li, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 8, pp. 701-721
Closed Access | Times Cited: 4
Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells
Thomas Sevrin, Hiroaki Imoto, Sarah A. Robertson, et al.
Cell Reports (2024) Vol. 43, Iss. 9, pp. 114710-114710
Open Access | Times Cited: 4
Thomas Sevrin, Hiroaki Imoto, Sarah A. Robertson, et al.
Cell Reports (2024) Vol. 43, Iss. 9, pp. 114710-114710
Open Access | Times Cited: 4
Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer
Andrew J. Aguirre, Ben Z. Stanger, Anirban Maitra
Cancer Research (2024) Vol. 84, Iss. 18, pp. 2950-2953
Closed Access | Times Cited: 4
Andrew J. Aguirre, Ben Z. Stanger, Anirban Maitra
Cancer Research (2024) Vol. 84, Iss. 18, pp. 2950-2953
Closed Access | Times Cited: 4
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer
Jincheng Han, Jiaqian Xu, Yonghong Liu, et al.
Genes & Development (2023) Vol. 37, Iss. 17-18, pp. 818-828
Open Access | Times Cited: 10
Jincheng Han, Jiaqian Xu, Yonghong Liu, et al.
Genes & Development (2023) Vol. 37, Iss. 17-18, pp. 818-828
Open Access | Times Cited: 10
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
Ivan Ranđelović, Kinga Nyíri, Gergely Koppány, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2572-2572
Open Access | Times Cited: 2
Ivan Ranđelović, Kinga Nyíri, Gergely Koppány, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2572-2572
Open Access | Times Cited: 2
Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, et al.
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 298-314
Closed Access | Times Cited: 2
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, et al.
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 298-314
Closed Access | Times Cited: 2
